rigosertib Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group
Sitenames

Any (1)

Phase 1/2 (1)

Interventional (1)

Icahn School of Medicine at Mount Sinai (1)

No (1)

No (1)

Adult (18+) (1)

icahn (1)
medicin (1)
mount (1)
school (1)
sinai (1)

I am/have/had

I am/have/hadsmall cell lung cancer

I am/have/hadcancer

I am/have/hadmeasurable disease

I am/have/hadlung cancer

I am/have/hadlung adenocarcinoma

I am/have/hadstage iv lung adenocarcinoma

I am/have/hadbilateral oophorectomy

I am/have/hadcore needle biopsy

I am/have/hadmetastatic lung adenocarcinoma

I am/have/hadoophorectomy

I am/have/hadhysterectomy

I am/have/haddrug test

I am/have/hadtubal ligation

I am/have/hadnon-small cell lung cancer

I am/have/hadadenocarcinoma

I am/have/hadserum pregnancy test

I am/have/hadkras

added new label for I am/have/had

more

I am looking for

I am looking fornivolumab

I am looking forkras

I am looking forrigosertib

I am looking forplatinum doublet

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Endocrinology
Recruiting

Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

A Phase1/2a Study of Rigosertib plus Nivolumab in Stage IV Lung Adenocarcinoma Patients with KRAS Mutation who Progressed on First-Line Treatment

nivolumab

small cell lung cancer

cancer

measurable disease

lung cancer

0 views
16 Feb, 2024
1 location

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2025 All rights reserved.